PHASQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHASQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PhaseBio Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2022 was $-419.60 Mil.
PhaseBio Pharmaceuticals's quarterly retained earnings declined from Dec. 2021 ($-391.79 Mil) to Mar. 2022 ($-402.94 Mil) and declined from Mar. 2022 ($-402.94 Mil) to Jun. 2022 ($-419.60 Mil).
PhaseBio Pharmaceuticals's annual retained earnings declined from Dec. 2019 ($-162.16 Mil) to Dec. 2020 ($-260.72 Mil) and declined from Dec. 2020 ($-260.72 Mil) to Dec. 2021 ($-391.79 Mil).
The historical data trend for PhaseBio Pharmaceuticals's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhaseBio Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Retained Earnings | Get a 7-Day Free Trial | -99.07 | -122.91 | -162.16 | -260.72 | -391.79 |
PhaseBio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Retained Earnings | Get a 7-Day Free Trial | -316.76 | -348.68 | -391.79 | -402.94 | -419.60 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
PhaseBio Pharmaceuticals (OTCPK:PHASQ) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Glen Burkhardt | officer: VP, Human Resources | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355 |
Jonathan Birchall | officer: Chief Commercial Officer | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355 |
William D. Humphries | director | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044 |
Clay Thorp | director | C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Edmund Harrigan | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Caroline M Loewy | director | 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Peter Justin Klein | director | 5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
David James Ballance | officer: VP, Research and Sci. Affairs | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
Michael York | officer: VP, Corporate Development | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
John Sang Lee | officer: Chief Medical Officer | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
Susan Elizabeth Arnold | officer: VP, Preclinical and Chem | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355 |
Kristopher Hanson | officer: VP, Head of Legal | C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355 |
From GuruFocus
By Business Wire Business Wire • 05-13-2021
By Business Wire Business Wire • 05-16-2022
By Business Wire Business Wire • 04-07-2022
By Business Wire Business Wire • 05-17-2021
By Business Wire Business Wire • 04-04-2022
By Business Wire Business Wire • 12-21-2021
By Business Wire Business Wire • 11-15-2021
By Business Wire Business Wire • 06-17-2021
By Business Wire Business Wire • 11-18-2021
By Business Wire Business Wire • 05-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.